Kura Oncology shares long-term FIT-001 data on darlifarnib-cabozantinib combo in advanced kidney cancer at KCRS 2026

Kura Oncology, Inc.

Kura Oncology, Inc.

KURA

0.00
  • Kura Oncology flagged updated long-term Phase 1a data for darlifarnib with cabozantinib in advanced clear cell renal cell carcinoma.
  • Results from the FIT-001 study will be presented in an oral session at the Kidney Cancer Research Summit on July 24, 2026.
  • A randomized Phase 1b trial comparing the combination versus cabozantinib alone is enrolling in the U.S. and EU.
  • Management plans a virtual investor call on July 27, 2026 to discuss the RCC program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607140702PRIMZONEFULLFEED9761621) on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.